Inc

Rapid HIV Testing Increases Possibility of Treatment

According to a November, 2005 joint press release from UNAIDS (Joint United Nations Programme on HIV/AIDS) and the World Health Organization, the number of people living with HIV globally reached an estimated high of 40.3 million people in 2005, with over 3 million deaths caused by AIDS. The latest data from...

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference

BETHESDA, Md., July 05, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, today announced that Dr. Christian Itin,President and Chief Executive Officer of Micromet, Inc., willpresent at the 3rd Annual C.E. Unterberg, Towbin Emerging GrowthConf...

Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference

RICHMOND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approvalof drugs for the treatment of metabolic diseases with unmetmedical needs, today announced that it will present at thisweek's C.E. Unterberg, Towbin (CEUT) Emerging GrowthOpportunities Conference in New York City. The conference, to be held at the Mandarin...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...

Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, presentedposter presentations at the 5th International Society for Stem CellResearch Annual Meeting (ISSCR) in Cairns, Queensland, Australiafrom June 17-20 and at the 13th Annual Meeting of the InternationalSociety for Cel...

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated(Nasdaq:INSM), a biopharmaceutical company focused on thedevelopment and approval of drugs for the treatment of metabolicdiseases with unmet medical needs, today noted the publication ofpromising results of research from three universities regarding thepotential role of insulin-like growth factor binding protein-3(IGFBP-3) in...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Women Report Partner's Symptoms Negatively Affect Relationship BOCA RATON, Fla., June 25, 2007 /PRNewswire/ -- Results of a newnationwide survey show that more than half of women whose malepartners have symptoms of a medical condition known as lowtestosterone incorrectly attribute them to the normal course ofaging. The survey also found that, while women believe their malepartner's sympto...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- KeryxBiopharmaceuticals, Inc. today announced that abstracts related toSulonex(TM) (sulodexide oral gelcap) have been selected forpublication or presentation during the poster sessions scheduled totake place at the upcoming American Diabetes Association (ADA) 67thAnnual Scientific Sessions and exposition at the McCormick PlaceLakeside Cen...

Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting

Company-Sponsored Investor Briefing and Webcast to FollowPresentation DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- BiodelInc. today announced plans to present clinical results of itsleading product candidate, VIAject(TM), at the 67th Annual AmericanDiabetes Association (ADA) Scientific Sessions, to be held inChicago, June 22 through June 26. Biodel's oral presentation at...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc.today is presenting data from an open-label extension of its PhaseIIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD)at the Alzheimer's Association's International Conference onPrevention of Dementia in Washington, D.C. Consistent with thefindings of earlier clinical and preclinical studies, AC-1202 wasshown to...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - MGI Pharma, Inc.(Nasdaq:MOGN), a biopharmaceutical company focused in oncology andacute care, today provided highlights of data presentations madeduring the 2007 American Society of Clinical Oncology (ASCO) AnnualMeeting. Dacogen (decitabine) for Injection was the subject of fiveposters including the presentation of efficacy data in olderpatients with...

Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial

CALGARY, June 05, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announced today positive results fromits U.S. Phase I clinical trial examining the systemicadministration of REOLYSIN(R) in patients with advanced cancers.The results indicate that REOLYSIN(R) can be delivered systemicallyto patients with advanced and metastatic cancers and causeanti-tumour activity.</p...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers atMolecular Insight Pharmaceuticals today announced the presentationof preclinical data on MIP-1072, a radiolabeled, small moleculemolecular imaging pharmaceutical in development for diagnosis andstaging of prostate cancer at the 54th annual meeting of theSociety of Nuclear Medicine (SNM) in Washington, D.C. MIP-1072 isone of two...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Molecular InsightPharmaceuticals, Inc. (NASDAQ: MIPI) announced today that thecompany will present the results of several preclinical studies atthe 54th annual meeting of the Society of Nuclear Medicine (SNM) inWashington, D.C. The presentations include data on Azedra(TM)(Ultratrace (131)I-MIBG), the company's clinical-stage, targetedradiothe...

Oncolytics Biotech Inc.'s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference

CALGARY, June 01, 2007 /PRNewswire-FirstCall/ - Researchcollaborators with Oncolytics Biotech Inc. ("Oncolytics") arescheduled to deliver a poster presentation covering REOLYSIN(R)clinical trial data at the American Society of Clinical Oncology(ASCO) Annual Meeting, to be held June 1-5, 2007 in Chicago. Thedata cover final results of Oncolytics' U.K. Phase I systemicadministration trial....

Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., May 25, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced that several abstracts featuring itsoncology products, Genasense(R) (oblimersen sodium) Injection, andGanite(R) (gallium nitrate injection), will be presented at the43rd annual meeting of the American Society of Clinical Oncology(ASCO) in Chicago, June 1-5, 2007. The abstracts include thefollowing:...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc.(Nasdaq: IMGN), a biopharmaceutical company that develops targetedanticancer therapeutics using its Tumor-Activated Prodrug (TAP)technology, today announced that clinical findings for threedifferent TAP compounds for the treatment of solid tumors are to bereported at the 43rd American Society of Clinical Oncology (ASCO)Annual...

ProtoKinetix's AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 -ProtoKinetix Inc. (OTCBB:PKTX) has just received the results ofstudies conducted by ITTEC Stem, Inc. at the University of Finland.These outstanding results using AAGP(TM) in the cryopreservationprocess for stem cells demonstrate the vital importance of thismolecule in the rapidly expanding stem cell industry. This is thefirst serie...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interactionwith paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration ofpaliperidone extended-release (ER) tablets, blood levels of thedrug were not affected when given with a common antidepressant,according to new data presented today at the 160th Annual Meetingof the American Psychiatric Association. Paroxetine,...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome

NEW YORK, May 22, 2007 /PRNewswire-FirstCall/ -- ForestLaboratories, Inc. and Cypress Bioscience, Inc. today announcedthat preliminary top-line results from a 1,196 patient randomized,three month, double-blind, placebo-controlled pivotal Phase IIIstudy demonstrate statistically significant therapeutic effects ofmilnacipran as a treatment of fibromyalgia syndrome. At this timethe companie...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that new data showimprovements in symptoms of decreased libido, energy levels anderectile function in 76 percent of hypogonadal men after switchingbrands of testosterone replacement gel therapy. Total testosteronelevels increased significantly in patients who switched toAuxilium's Testim(R)...

Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD

Phase III clinical trial may commence shortly CARMIEL, Israel, April 18, 2007 /PRNewswire-FirstCall/ ---Protalix BioTherapeutics, Inc. today announced that it has receivedwritten notice from the United States Food and Drug Administration(FDA) that it may initiate a Phase III clinical trial in the UnitedStates of its lead product candidate, prGCD, a proprietary plantcell expressed recombin...

FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.

Company Misrepresented Prescription PainReliever to Health Care Professionals ROCKVILLE, Md., May 10, 2007-The U.S. Food and DrugAdministration's (FDA) Office of Criminal Investigations (OCI)announced today that The Purdue Frederick Company, Inc. has agreedto pay more than $700 million to resolve criminal charges and civilliabilities in connection with...

New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits

- Bifantis shows ability to limit inflammation in models ofarthritis and Salmonella infection, according to data presented atDigestive Disease Week - WASHINGTON, May 21, 2007 /PRNewswire/ -- The biotechnologycompany Alimentary Health today announced results from two studiesthat demonstrate the anti-inflammatory activity of a naturalprobiotic bacterial strain of human origin, Bifantis(R)(...

Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in Preclinical Studies

LUCCA, ITALY, ­ May 14, 2007-Acceleron Pharma, Inc., abiopharmaceutical company developing therapeutics for the treatmentof musculoskeletal, metabolic and cancer-related diseases, todayannounced results of a preclinical study with ACE-031 thatdemonstrated the ability of the compound to increase muscle massand strength in normal mice and in murine models of musculardystrophy. ACE-031...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results of a preclinical study withACE-031 that demonstrated the ability of the compound to increasemuscle mass and strength in normal mice and in murine models ofmuscular dystrophy...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

-- Large multi-year, multi-hospital retrospective database analysisdemonstrates RDS treatment with Curosurf(R) (poractant alfa)Intratracheal Suspension provides significantly improved neonatalsurvival -- NAPA, Calif. and PARMA, Italy, May 07, 2007 /PRNewswire/ -- Datapresented today at the Pediatric Academic Societies' Annual Meetingdemonstrate that premature infants with neonatal Respira...

Accera, Inc. Announces Results of Phase II Study in Alzheimer's Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- Accera Inc. ispresenting topline data today from its Phase IIb study of its leadcompound AC-1202 in Alzheimer's disease (AD) at the AmericanAcademy of Neurology (AAN) 59th Annual Meeting in Boston. Judged bythe AAN to be in the top five percent of the program, the data willalso be featured in the Scientific Highlights Plenary Session. <p...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

Data published today in the Journal of the National CancerInstitute BASEL, Switzerland, 2 May 2007 - In a study published today inthe Journal of the National Cancer Institute, the innovative cancerdrug MabThera was shown to improve overall survival in patientswith lymphoma regardless of the chemotherapy regimen used.1 Thereview further s...

Accera, Inc. to Present Results of Phase II Study in Alzheimer's Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- Accera Inc.announced today that topline data from its Phase IIb study of itslead compound AC-1202 in Alzheimer's disease (AD) will be presentedat the annual meeting of the American Academy of Neurology (AAN) inBoston. Judged by the AAN to be in the top five percent of theprogram, the data will also be featured in the ScientificHighlights...

Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced that newpreclinical research demonstrating a role in chronic inflammatoryautoimmune disease for High Mobility Group Box-1 protein (HMGB1), apro-inflammatory mediator and nuclear DNA-binding protein, will bepublished in the May 2007 issue of Nature Immunology. Thepublication demonstrat...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announces that a poster by Dr. MaureenE. Lane et al. of , New York, entitled "In Vivo Synergy betweenOncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116Xenografts" is scheduled to be presented today at the AmericanAssociation for Cancer Research (AACR) Annual Meeting in LosAngeles, CA. The m...

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized,double-blind, parallel-group Phase II study of 90 patientscomparing a 40 mg dose of COPAXONE(R) given daily to the currentlyapproved COPAXONE(R) 20 mg dose showed a 38 percent greaterreduction in inflammatory disease activity as measured by magneticresonance images (MRI) of the brain. In addition, patients takingCOPAXONE(R) 40...